Objective:To observe the clinical efficacy of Buxu Ruangan Decoction in the treatment of primary biliary cirrhosis with poor response to ursodeoxycholic acid. MethodsSixty-two patients of primary biliary cirrhosis with poor response to ursodeoxycholic acid were randomly divided into the treatment group (n=32) and control group (n=30). The control group was treated with routine therapy,and the treatment group was treated with Buxu Ruangan Decoction based on the treatment for the control group,with a course of 24 weeks. The clinical efficacy was observed,and the changes on the chronic liver disease questionnaire (CLDQ) score,liver function indexes,liver fibrosis indexes and fibroscan test were compared.  Results: ①The total effective rates was 87.5% in the treatment group and 63.3% in the control group,and the clinical efficacy of the treatment group was better than that of the control group(P＜0.05). ②After treatment,the CLDQ score was decreased in both groups(P＜0.05),and there was statistically significant difference on the CLDQ score between the two groups(P＜0.05). ③After treatment,the levels of ALT,AST,TBIL,GGT,ALP and TBA were decreased in both groups(P＜0.05),and there were statistically significant differences on the levels of all liver function indexes between the two groups(P＜0.05). ④After treatment,the levels of HA,LN,PC-Ⅲ and Ⅳ-C and the value of liver stiffness measurement(LSM)were decreased in both groups(P＜0.05),and the levels of HA and Ⅳ-C and the LSM value in the treatment group were lower than those in the control group(P＜0.05).  Conclusion:Buxu Ruangan Decoction shows good clinical efficacy in the treatment of primary biliary cirrhosis with poor response to ursodeoxycholic acid,which can improve the liver function and liver fibrosis indexes,decrease the LSM value and enhance the quality of life.